Compounds > o-isovaleryl propranolol
Page last updated: 2024-11-06

o-isovaleryl propranolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

O-isovaleryl propranolol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID86121
MeSH IDM0213154

Synonyms (11)

Synonym
o-isovaleryl propranolol
[1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-yl] 2,2-dimethylpropanoate
propanoic acid, 2,2-dimethyl-, 1-(((1-methylethyl)amino)methyl)-2-(1-naphthalenyloxy)ethyl ester
1-(((1-methylethyl)amino)methyl)-2-(1-naphthalenyloxy)ethyl 2,2-dimethylpropanoate
111422-10-7
o-isovaleryl-pl
AKOS024358215
1-[(naphthalen-1-yl)oxy]-3-[(propan-2-yl)amino]propan-2-yl 2,2-dimethylpropanoate
DTXSID40912158
1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-yl 2,2-dimethylpropanoate
1-(isopropylamino)-3-(naphthalen-1-yloxy)propan-2-yl pivalate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The enantioselective oral bioavailability of propranolol (PL) from 0-isovaleryl-PL was determined and compared with parent PL in beagle dogs."( Enantioselective oral bioavailability of 0-isovaleryl propranolol as a potential prodrug of propranolol.
Imai, T; Otagiri, M; Shameem, M, 1992)		0.28
"The bioavailability of propranolol (PL) after oral administration of ester-type prodrug was compared in rat and dog, and the possible reason for species difference was investigated."( Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.
Aso, T; Imai, T; Otagiri, M; Yoshigae, Y, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bis(4-nitrophenyl)phosphate
bis(4-nitrophenyl)phosphate: RN given refers to parent cpd		2.0310aryl phosphate
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		9.4851naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
4-nitroaniline
[no description available]		2.0310nitroanilinebacterial xenobiotic metabolite
4-nitrophenyl acetate
[no description available]		2.0310C-nitro compound;
phenyl acetates
1-leucine-4-nitroanilide
1-leucine-4-nitroanilide: substrate for arylamidase; RN given refers to cpd without isomeric designation		2.0310
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials